EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis

Elias Seidl, Andrew Zikic, Srdjan Micic, Rianne de Vries, Julie Avolio, Alexander Moeller, Felix Ratjen, Hartmut Grasemann

Journal of Cystic Fibrosis · 2026-07 · 25 (4) · 695-701

DOI: 10.1016/j.jcf.2026.03.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von Elias Seidl und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, University Children's Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quinolones, Aminophenols, Benzodioxoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Breath profile analysis of volatile organic compounds (VOCs) by electronic nose (eNose) technology can distinguish between healthy individuals and people with cystic fibrosis (pwCF). It remains, however, unclear whether CFTR modulator therapy, that corrects the underlying defect in treated pwCF, alters the exhaled breath profiles. METHODS: In this prospective longitudinal study, eNose-derived exhaled breath profiles were obtained using the SpiroNose® (Breathomix, Leiden, The Netherlands) from 61 CF children before starting therapy with elexacaftor/tezacaftor/ivacaftor (ETI), and at follow-up visits less than 3 and more than 6 months after ETI initiation. Routine clinical outcomes and airway microbiology were assessed at all visits. Twenty-six healthy controls provided single measurements. Longitudinal SpiroNose sensor data were analyzed using linear mixed-effects models and permutational multivariate analysis of variance (PERMANOVA), and exploratory mixed-effects models to test for associations with Staphylococcus aureus (SA) airway infection and clearance. RESULTS: ETI led to improved sweat chloride concentrations, pulmonary function (ppFEV1) and BMI, but no significant changes in SpiroNose sensor signals were observed during follow-up. SpiroNose sensor signals reliably discriminated healthy controls from CF children at baseline and at follow-up on ETI, with consistent differences in multiple SpiroNose sensors. SA airway infection was captured (sensor S7), whereas SA clearance did not result in measurable changes in SpiroNose signals. CONCLUSIONS: CFTR modulator therapy with ETI does not significantly alter eNose-derived VOC breath profiles in children with CF. The ability of the eNose to distinguish CF from healthy controls remains unchanged after ETI initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuinolonesAminophenolsBenzodioxolesIndolesPyrrolidinesVolatile Organic CompoundsPyridinesHumansFemaleBreath TestsMaleChildDrug CombinationsProspective StudiesLongitudinal StudiesAdolescentChloride Channel Agonists

Stichwörter der Autor:innen

CFTR modulator treatmentCystic fibrosisElectronic noseRespiratory diseaseRespiratory infectionsVolatile organic compounds

Substanzen

QuinolonesAminophenolsDrug CombinationsBenzodioxolesIndolesPyrrolidinesVolatile Organic CompoundsPyridinestezacaftor, ivacaftor drug combinationChloride Channel Agonists

Autor:innen und Institutionen

  • Department of Respiratory Medicine, University Children's Hospital Zurich, Zurich, Switzerland.
  • Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada.
  • Breathomix BV, Bargelaan 200, Leiden, CW 2333, The Netherlands.
  • Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, ON M5G 1 × 8, Canada and University of Toronto, Toronto, Canada.
  • Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada; Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, ON M5G 1 × 8, Canada and Univ…

Zitieren

APA

Seidl, E., Zikic, A., Micic, S., de Vries, R., Avolio, J., Moeller, A., Ratjen, F., & Grasemann, H. (2026). Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis. Journal of Cystic Fibrosis, 25(4), 695-701. https://doi.org/10.1016/j.jcf.2026.03.014

Vancouver

Seidl E, Zikic A, Micic S, de Vries R, Avolio J, Moeller A, et al. Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis. Journal of Cystic Fibrosis. 2026;25(4):695-701. doi:10.1016/j.jcf.2026.03.014

BibTeX
@article{Seidl2026,
  author = {Seidl, Elias and Zikic, Andrew and Micic, Srdjan and de Vries, Rianne and Avolio, Julie and Moeller, Alexander and Ratjen, Felix and Grasemann, Hartmut},
  title = {Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  volume = {25},
  number = {4},
  pages = {695--701},
  doi = {10.1016/j.jcf.2026.03.014}
}
Kostenlos starten →